RecruitingNCT06072690

Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease

The Impact of Dual Bronchodilation on Respiratory and Cardiovascular Systems in Patients With Newly Diagnosed Moderate-to-severe Chronic Obstructive Pulmonary Disease


Sponsor

Lithuanian University of Health Sciences

Enrollment

80 participants

Start Date

Apr 15, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Chronic obstructive pulmonary disease (COPD) is a lung condition characterized by chronic respiratory symptoms (dyspnoea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (e.g. bronchitis, bronchiolitis) and/or alveoli (emphysema) that lead to persistent, often progressive, airflow obstruction. It is a major cause of disability and death worldwide. Moreover, people with COPD often have cardiovascular diseases (CVDs) that are associated with increased risk for hospitalization and prolonged stay as well as all-cause and CVD-related mortality. Nevertheless, CVDs in patients with COPD are tend to be underestimated in clinical practice. Mechanisms that define the relation between COPD and cardiovascular morbidity include lung hyperinflation, hypoxia, pulmonary hypertension, systemic inflammation and oxidative stress, exacerbation, shared risk factors and COPD phenotypes. In the past years, some authors have announced that COPD treatment with dual bronchodilation may not only improve pulmonary function and quality of life, but also have a positive effect on cardiac function. However, there is a lack of studies with treatment-naïve patients that would describe the initial effect of dual bronchodilation on respiratory and cardiovascular systems. In this study we aimed to evaluate the effect of initial dual bronchodilation on the quality of life, respiratory and cardiovascular systems in patients with newly-diagnosed chronic obstructive pulmonary disease.


Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study examines the effects of COPD — a lung disease that causes breathing difficulties — on both the lungs and the heart. Researchers want to understand how newly diagnosed COPD affects both respiratory and cardiovascular function, with the goal of improving overall care. **You may be eligible if...** - You are 40 years or older - You have a smoking history of at least 10 pack-years - You have been newly diagnosed with COPD, with breathing test results showing moderate to severe airflow limitation (FEV1 30–79% of expected, and FEV1/FVC ratio below 70%) **You may NOT be eligible if...** - You have an active lung infection - You have a history of lung cancer - You have alpha-1 antitrypsin deficiency, interstitial lung disease, or previously diagnosed asthma - You have chronic respiratory failure requiring ongoing CO2 management - You are already receiving advanced COPD treatment (like triple inhaler therapy) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Lithuanian University of Health Sciences

Kaunas, Kaunas County, Lithuania

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06072690


Related Trials